CN-121975660-A - Triple probiotics and application thereof

Abstract

The invention relates to the technical field of microorganism technology and biological medicine, in particular to triple probiotics, a preparation method and application thereof, wherein the triple probiotics comprise at least one kind of probiotics of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an oxygen consumption-enzyme production-acid production synergistic chain, and through synergistic degradation of uric acid and inhibition of overgrowth of conditional pathogenic bacteria, the intestinal barrier function is enhanced, so that the blood uric acid level of asymptomatic hyperuricemia patients is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid production bacteria is increased, the ratio of escherichia coli to shigella is reduced, SIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension, exhaust and the like are reduced. In addition, the triple probiotics avoid hepatotoxicity and nephrotoxicity caused by chemical medicines, and are suitable for long-term administration.

Inventors

• ZHANG LIQING
• WANG YAOYONG
• WANG GANG
• DENG SHENGDONG
• WANG JIANBAO
• NIU RUNHUA
• Qin Anlin
• WEN QIANYING

Assignees

• 山西省汾阳医院

Dates

Publication Date

20260505

Application Date

20260209

Claims (9)

1. 1. A triple probiotic comprising at least one probiotic of the genus bacillus, and lactobacillus acidophilus and bifidobacterium longum.
2. 2. The triple probiotic according to claim 1, wherein the mass ratio of the probiotics of the genus bacillus, the lactobacillus acidophilus and the bifidobacterium longum is 1 (0.5-1.5): 0.5-1.5.
3. 3. The triple probiotic according to claim 1, characterized in that the mass ratio of the probiotic bacteria of the genus bacillus, the lactobacillus acidophilus, the bifidobacterium longum is 1:1:1.
4. 4. The triple probiotic according to claim 1, wherein said probiotic of the genus bacillus comprises bacillus coagulans.
5. 5. The triple probiotic according to any one of claims 1 to 4, wherein the formulation of the triple probiotic is a live bacterial capsule, and the content of the probiotic in the live bacterial capsule is 1000-1500 hundred million/g.
6. 6. The triple probiotic according to any one of claims 1 to 4, wherein the formulation of the triple probiotic is a live bacterial capsule, and the content of the probiotic in the live bacterial capsule is 1200 hundred million/g.
7. 7. Use of a triple probiotic of any one of claims 1-6 in the treatment of hyperuricemia.
8. 8. Use of a triple probiotic of any one of claims 1-6 for the modulation of immune function.
9. 9. Use of a triple probiotic of any one of claims 1-6 for the modulation of Th17/Treg cell balance.

Description

Triple probiotics and application thereof Technical Field The invention relates to the technical field of microorganism technology and biological medicine, in particular to triple probiotics and application thereof. Background Hyperuricemia (hyperuricemia, HUA) has become the second most metabolic disease in our country next to diabetes. Epidemiological surveys show that the prevalence of HUA in adults in our country is about 14.0%, 60-70% of which are in the asymptomatic stage. Continuously rising blood uric acid (serum uric acid, SUA) is closely related to hypertension, diabetes, obesity, dyslipidemia, etc., and can induce gout, as well as an independent risk factor for various health complications, including cardiovascular and cerebrovascular diseases, kidney diseases, metabolic syndrome, etc. The current clinical intervention means for hyperuricemia mainly comprise: (1) Inhibiting uric acid generation (such as allopurinol and febuxostat), but has adverse reactions such as rash, hepatotoxicity, cardiovascular events and the like; (2) Uric acid excretion-promoting agents (such as benzbromarone), contraindicated for patients with renal dysfunction and can induce urinary stones; (3) Lifestyle interventions (low purine diets, exercise), poor patient compliance and limited amplitude reduction. It can be seen that the existing clinical intervention means for hyperuricemia are limited, and the side effects of the medicament are more, so that many people cannot keep taking the medicament. In view of this, how to provide a safe and effective clinical intervention means for hyperuricemia is a technical problem that needs to be solved at present. Disclosure of Invention In order to solve the problem of more side effects of hyperuricemia clinical drug intervention in the prior art, the invention provides the triple probiotics which obviously reduces the blood uric acid level of asymptomatic hyperuricemia patients by cooperatively degrading uric acid, inhibiting overgrowth of conditional pathogenic bacteria and enhancing the intestinal barrier function, thereby solving the problem of more side effects of hyperuricemia clinical intervention means in the prior art. The technical scheme adopted for solving the technical problems is as follows: a triple probiotic comprising at least one probiotic of the genus bacillus, and lactobacillus acidophilus and bifidobacterium longum. Optionally, the mass ratio of the probiotics of the bacillus, the lactobacillus acidophilus and the bifidobacterium longum is 1 (0.5-1.5) to 0.5-1.5. Optionally, the mass ratio of the probiotics of the bacillus genus, the lactobacillus acidophilus and the bifidobacterium longum is 1:1:1. Optionally, the probiotic bacteria of the genus bacillus include bacillus coagulans. Optionally, the formulation of the triple probiotics is a live bacteria capsule, and the content of probiotics in the live bacteria capsule is 1000-1500 hundred million/g. Optionally, the formulation of the triple probiotics is a live bacteria capsule, and the content of probiotics in the live bacteria capsule is 1200 hundred million/g. Another object of the present invention is to provide the use of a triple probiotic as described above in the treatment of hyperuricemia. It is a further object of the present invention to provide a use of a triple probiotic as described above in the modulation of immune function. It is a further object of the present invention to provide the use of a triple probiotic as described above for the regulation of Th17/Treg cell balance. The beneficial effects of the invention are as follows: The triple probiotics provided by the invention form an oxygen consumption-enzyme production-acid production synergistic chain, and through synergistic degradation of uric acid and inhibition of overgrowth of conditional pathogenic bacteria, the intestinal barrier function is enhanced, so that the blood uric acid level of asymptomatic hyperuricemia patients is obviously reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid bacteria is improved, the ratio of escherichia coli to shigella is reduced, SIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension, exhaust and the like are reduced. In addition, the triple probiotics avoid hepatotoxicity and nephrotoxicity caused by chemical medicines, and are suitable for long-term administration. Drawings The invention will be further described with reference to the drawings and examples. FIG. 1 is a scaleless network illustration of the best soft threshold in a weighted correlation network analysis (WGCNA) in an embodiment of the present invention, with the left graph showing the best soft threshold and the right graph showing the network connectivity for different soft thresholds; FIG. 2 is a graph showing the results of module aggregation of the first 50% of the variance in the examples of the present invention; FIG. 3 shows the clustering resu